Search

everythinglearnresearchcommunity

for

Search:↓

The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.

A 30-year-old man saw improved hair density and texture after three months using Minoxidil, Finasteride, and ketoconazole shampoo, despite initial side effects. He experienced increased body hair and libido and is satisfied with the results despite the high cost in Turkey.

The user is considering switching from Finasteride to Dutasteride for better hair regrowth, despite concerns about potential shedding and side effects. Opinions vary, with some suggesting the switch for stronger results and others advising caution due to possible side effects and the importance of consulting a doctor.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Effective treatments for hair loss include finasteride, dutasteride, RU58841, and minoxidil. Starting treatment early is important, and users discuss different brands, forms, and side effects.

Stopping minoxidil and finasteride for three months caused significant hair loss. The user resumed treatment with 2.5mg oral minoxidil and 0.6mg finasteride and plans to update on progress in three months.

There is concern about a potential ban on finasteride in the EU, but many believe it is unlikely unless serious side effects are found. Users rely on finasteride for hair loss and other health benefits, and a petition has been created to oppose any restrictions.

The user is treating hair loss with 1mg finasteride every other day, daily topical minoxidil, and weekly derma rolling, and is considering using hair fibers for special occasions. There is a discussion about the initial shedding phase of minoxidil treatment and the importance of consistent photo conditions to track progress.

The conversation discusses the risks and methods of ingesting liquid minoxidil for hair loss. Concerns include dosing accuracy, safety of ingredients, and potential side effects compared to using oral minoxidil tablets.

User tried Minoxidil and Finasteride for hair loss with no success and considers giving up. Others suggest continuing treatment, trying hair transplant, or embracing baldness.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

Taking topical minoxidil orally for hair loss treatment, discussing safety, dosing, side effects, and FAQs. Users express concerns about safety and potential heart damage, while others share experiences and results.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The user is experiencing hair thinning and shedding despite no family history of male pattern baldness. They are considering starting treatments like Minoxidil or finasteride.

The user has been using minoxidil 5% and finasteride 0.1% topically, along with oral minoxidil and finasteride, for three months without major improvement in hair loss. They are also taking vitamin D3, B12, iron, and zinc supplements.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A 24-year-old has been using finasteride, oral minoxidil, and microneedling for hair loss. They reduced minoxidil due to heartburn and are considering a hair transplant.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.